<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553420</url>
  </required_header>
  <id_info>
    <org_study_id>ECLip Registry</org_study_id>
    <nct_id>NCT03553420</nct_id>
  </id_info>
  <brief_title>Registry for Patients With Lipodystrophy</brief_title>
  <acronym>ECLip Registry</acronym>
  <official_title>Osse Registry for Patients With Lipodystrophy Run by the European Consortium of Lipodystrophies (ECLip)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sorbonne Université, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Endocrinology Research Centre, Moscow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Amsterdam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Timone (MARSEILLE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar De São João, E.P.E.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jagiellonian University, Krakow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dokuz Eylul University, Izmir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Santiago de Compostela</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Münster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cyprus Institute of Neurology and Genetics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Piemonte Orientale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the lack of knowledge on lipodystrophies, the medical and social responsibility for the
      persons affected by it calls for the monitoring of the progression over long periods of time.
      Sensible clinical and basic research into rare diseases such as lipodystrophy is only
      possible in multi-location networks with sufficient case numbers. Also, reliable information
      on the incidence of certain manifestation patterns, health status, etc. is of utmost
      importance for health care and health policy in this rare disease.

      Therefore, the European Consortium of Lipodystrophies (ECLip), an association of European
      experts on lipodystrophy, has launched a registry (OSSE) for lipodystrophies which is
      committed to help to improve the research conditions by consolidating this kind of
      information in a registry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As lipodystrophies are rare diseases subdivided into yet rarer sub-groups, research in this
      field requires international co-operation.

      The European Consortium of Lipodystrophy (ECLip) consists of an association of European
      experts in the field of lipodystrophy. It has set up a Registry Board to implement a registry
      for patients with lipodystrophy using the Open Source Software OSSE (Open Source Registry
      System for Rare Diseases in the EU), which is a web based platform focused on a federated
      approach that allows to perform distributed searches which are designed to comply data
      protection requirements and preserve data sovereignty. To ensure data protection, medical and
      identifying data will be stored on two different servers both run by the Institute for
      Epidemiology and Medical Biometry of the University of Ulm.

      Medical centers from all over the world where patients are treated with lipodystrophy are
      invited to join the ECLip Registry and to become ECLip Registry members. Upon registration,
      they can enter patient data after they have obtained local ethic committee permission and the
      patient in question has given written consent to this. Data entry is done at the individual
      locations via a web-based user interface. Identifying data are recorded directly into the
      identity management system. Communication between the identity management and the OSSE
      registry happens via a web browser.

      The aim of the patient registry is to compile data on the natural history of each different
      sub-group of lipodystrophies, their comorbidities, treatment options used and medical and
      quality of life out-come for the patients. For this, the following data retrieved from
      regular patient visits are collected:

        -  Precise diagnosis including moleculargenetic results

        -  Clinical presentation and comorbidities

        -  Laboratory changes and results of diagnostic procedures

        -  Natural course of the disease including age at onset of disease and comorbidities

        -  Family history

      Research within this registry can be performed by participating clinicians/researchers and
      third parties after a research proposal has be accepted by the responsible committee of the
      ECLip. The registry aims to answer the following questions

        -  new insights into the pathophysiology of lipodystrophy

        -  improve therapeutic options for the patients

        -  compile information material for patients, families and relevant professionals
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2017</start_date>
  <completion_date type="Anticipated">January 2068</completion_date>
  <primary_completion_date type="Anticipated">January 2068</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>50 Years</target_duration>
  <primary_outcome>
    <measure>Age at death</measure>
    <time_frame>after 20 years</time_frame>
    <description>patients are followed regularly, age at death (years) will be documented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in somatic comorbidities under standard treatment</measure>
    <time_frame>yearly for 50 years</time_frame>
    <description>standardized physical examination, laboratory and instrument based tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genotype-phenotype correlation for patients with familial lipodystrophy</measure>
    <time_frame>every 5 years for 50 years</time_frame>
    <description>molecular genetic results will be compared to results from standardized physical examination, laboratory and instrument based tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>age at onset of metabolic complications</measure>
    <time_frame>yearly for 50 years</time_frame>
    <description>metabolic complications will be assessed via standardized physical examination, laboratory and instrument based tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>age at onset orthopedic complications</measure>
    <time_frame>yearly for 50 years</time_frame>
    <description>orthopedic complications will be assessed via standardized physical examination, laboratory and instrument based tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>age at onset neuromuscular complications</measure>
    <time_frame>yearly for 50 years</time_frame>
    <description>neuromuscular compliations will be assessed via standardized physical examination, laboratory and instrument based tests</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Lipodystrophy Acquired</condition>
  <condition>Lipodystrophy Congenital</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all patients with lipodystrophy not due to anti-retroviral drugs presenting to a
        participating center might be entered
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  lipodystrophy

        Exclusion Criteria:

          -  lipodystrophy due to anti-retroviral drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Wabitsch, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Araujo-Vilar, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santiago de Compostela University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia von Schnurbein, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriele Nagel, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camille Vatiers, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pierre et Marie Curie School of Medicine (Paris)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Christine Vantyghem, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lille University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Ceccarini, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrine Unit, University Hospital of Pisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jannik Schaaf, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ekaterina Sorkina, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology Research Centre, Moscow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Savage, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge Metabolic Research Laboratories</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia von Schnurbein, Dr.</last_name>
    <phone>0049 731 500</phone>
    <phone_ext>57401</phone_ext>
    <email>julia.schnurbein@uniklinik-ulm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Wabitsch, Prof. Dr.</last_name>
    <phone>0049 731 500</phone>
    <phone_ext>57401</phone_ext>
    <email>martin.wabitsch@uniklinik-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lille University</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Christine Vantyghem, Prof.</last_name>
      <email>Marie-Christine.VANTYGHEM@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's hospital la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Levy, Prof.</last_name>
      <email>nicolas.levy@univ-amu.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pierre et Marie Curie School of Medicine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille Vatier, Dr.</last_name>
      <email>camille.vatier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Human Genetics, Martin Luther University Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katrin Hoffmann</last_name>
      <email>katrin.hoffmann@uk-halle.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine (Endocrinology and Nephrology), University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstanze Miehle, Dr.</last_name>
      <email>Konstanze.Miehle@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med. Klinik B für Gastroenterologie und Hepatologie, Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hartmut Schmidt, Prof.</last_name>
      <email>hepar@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Elena Vorona</last_name>
      <email>'Elena.Vorona@ukmuenster.de'</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dept for Pediatrics and Adolescent Medicine, University of Ulm: Interdisciplinary obesity clinic</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Wabitsch, Prof.</last_name>
      <phone>0049 731 500</phone>
      <phone_ext>57401</phone_ext>
      <email>martin.wabitsch@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Julia von Schnurbein, Dr. med.</last_name>
      <phone>0049 731 500</phone>
      <phone_ext>57401</phone_ext>
      <email>julia.schnurbien@uniklinik-ulm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Wabitsch, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia von Schnurbein, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinology Unit, Department of Clinical and Medical science, S. Orsola-Malpighi Hospital , University of Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Gambinieri</last_name>
      <email>alessandra.gambineri@aosp.bo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrine Unit, University Hospital of Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Ceccarini, Dr.</last_name>
      <email>giovanni.ceccarini@unipi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tor Vergata University - Policlinico of Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giusepe Novelli</last_name>
      <email>novelli.g@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center, University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raoul Hennekam, Prof.</last_name>
      <email>r.c.hennekam@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maciej Malecki</last_name>
      <email>malecki_malecki@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paula Freitas</last_name>
      <email>paula_freitas@sapo.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinology Research Centre</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Sorkina, MD</last_name>
      <email>sorkina@bk.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santiago de Compostela University</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Araujo-Vilar, Prof. Dr.</last_name>
      <email>david.araujo@usc.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University School of Medicine</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baris Akinci</last_name>
      <email>barisakincimd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cambridge Metabolic Research Laboratories</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Savage, Prof.</last_name>
      <email>dbs23@medschl.cam.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Claire Adams</last_name>
      <email>ca337@medschl.cam.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Julia von Schnurbein</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>lipodystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy, Congenital Generalized</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researches participating in the ECLip registry and third parties independently can request to perform research with the data.</ipd_description>
    <ipd_time_frame>As soon as data is entered into the registry, request for data analysis can be handed in.</ipd_time_frame>
    <ipd_access_criteria>Researches participating in the ECLip registry and third parties independently can request to perform research with the data. For this a formal request for data analysis (data evaluation form; available from the Registry Board) has to be handed to the leader of the Registry Board who will pass it to all board members. These will form a proposal for the Registry members.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

